Foundation Medicine, Inc.
One Kendall Square
Suite B3501
Cambridge
Massachusetts
02139
United States
Tel: 617-418-2200
Fax: 617-418-2201
Website: http://www.foundationmedicine.com/
234 articles about Foundation Medicine, Inc.
-
Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/6/2024
Foundation Medicine, Inc., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
-
Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
12/14/2023
Foundation Medicine, Inc., announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer.
-
Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations
10/26/2023
Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.
-
Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
10/21/2023
Foundation Medicine, Inc., announced that it has expanded its partnership with Sequanta Technologies Co., Ltd. to provide genomic profiling services to support clinical research and the development of oncology therapies in China.
-
Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
10/19/2023
Foundation Medicine, Inc., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.
-
FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Pfizer’s BRAFTOVI® (encorafenib) in Combination With MEKTOVI® (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC
10/12/2023
Foundation Medicine Inc. announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.
-
Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOne®Tracker
10/10/2023
FoundationOne ® Tracker is now available to all physicians in the United States seeking personalized monitoring of their patients’ response to treatment.
-
Foundation Medicine Announces the Launch of FoundationOne®RNA Assay for Research and Investigational Use
9/6/2023
Foundation Medicine Inc., announced the launch of the research use and investigational use versions of FoundationOne®RNA, its broad tissue-based RNA test.
-
Some experts question the value of recently issued FDA guidance that aims to address gaps in the quality of unapproved laboratory tests for cancer.
-
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
8/14/2023
Foundation Medicine Inc., announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx to be used as a companion diagnostic for Janssen Biotech, Inc. AKEEGA™, which was approved by the FDA for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
-
Foundation Medicine Announces Leadership Appointments - June 15, 2023
6/15/2023
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced organizational changes to the executive leadership team to position the company for continued growth and usher in the next era of cancer care.
-
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib)
6/9/2023
U.S. Food and Drug Administration (FDA) Approves FoundationOne ® Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer.
-
Foundation Medicine Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Selected Marketed and Pipeline Treatments
6/5/2023
Foundation Medicine, Inc. today announced that it has entered a strategic collaboration with Merck KGaA, Darmstadt, Germany to develop FoundationOne ® Liquid CDx and FoundationOne ® CDx as companion diagnostics in the U.S. market for selected marketed and pipeline treatments.
-
Foundation Medicine Expands Monitoring Portfolio with Launch of FoundationOne®Monitor
6/2/2023
Foundation Medicine, Inc ., today announced the launch of its tissue-naïve circulating tumor DNA (ctDNA) monitoring assay, FoundationOne®Monitor, for research use in retrospective studies.
-
Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2023
Foundation Medicine, Inc., announced that the company and its collaborators will present 21 abstracts demonstrating the value of high-quality tumor profiling tests to inform cancer care at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6 in Chicago.
-
FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer
5/4/2023
Foundation Medicine, Inc., a leader in molecular profiling for cancer, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for EXKIVITY® (mobocertinib).
-
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
4/11/2023
Expanded collaboration aimed at developing FoundationOne CDx as a companion diagnostic for Bristol Myers Squibb’s investigational tyrosine kinase inhibitor, repotrectinib.
-
Foundation Medicine to Share 10 Abstracts at AACR23 Demonstrating the Unique Capabilities of Its Molecular Profiling Tests to Advance Precision Cancer Care
4/5/2023
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced that the company and its collaborators will present a total of 10 studies at the 2023 American Association for Cancer Research Annual Meeting from April 14-19 in Orlando, Florida.
-
Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care
1/19/2023
Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care.
-
Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Companion Diagnostic for XPOVIO® (selinexor)
1/10/2023
Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne ® CDx as a Companion Diagnostic for XPOVIO® (selinexor).